Search

file (10) (1)

OBI Information

News

HOMEWhat’s NewNews

2024.Oct.13

Corporate

Ascentawits Pharma announced the interim analysis results of the AST-3424 Phase II clinical efficacy and safety study in advanced HCC at the 2024 CSCO conference

2024.Sep.24

Corporate

Award & Certification​

OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards

2024.Aug.22

Corporate

The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs

2024.Aug.07

Corporate

OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

2024.Jul.30

Corporate

OBI Pharma: An Exciting Launching Pad for Young Scientists

2024.Jul.29

Corporate

OBI’s Proprietary ADC Platform GlycOBI® Seeks Collaborative Partnerships for Development

2024.Jul.26

Corporate

Vision: OBI Presents a Five-Year Strategic Plan

2024.Jul.25

Corporate

OBI Shares Opportunities and Challenges of ADC Development at BioAsia2024

2024.Jul.09

Corporate

OBI 's ADC Technology Platform GlycOBI® and Enzyme EndoSymeOBI® Two Trademarks Approved by Taiwan Intellectual Property Office

2024.Jun.28

Corporate

OBI Pharma shareholders’ meeting launches new company strategy and embraces transformation 

Announcements

Latest announcements

Events

Latest events